Correction: Field, M. et al. AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients

Correction: Field, M. et al. AbobotulinumtoxinA (Dysport^®), OnabotulinumtoxinA (Botox^®), and IncobotulinumtoxinA (Xeomin^®) Neurotoxin Content and Potential Implications for Duration of Response in Patients

Toxins (Basel). 2019 Feb 13;11(2):115. doi: 10.3390/toxins11020115.

¹ Ipsen Bioinnovation, Abingdon OX14 4RY, UK. g.field@oxb.com.
² Ipsen Bioinnovation, Abingdon OX14 4RY, UK. andrew.splevins@ipsen.com.
³ Ipsen Pharma, Cambridge, MA 02142, USA. philippe.picaut@ipsen.com.
⁴ TNO-CBRN Protection, 2288GJ Rijswijk, The Netherlands. marcel.vanderschans@tno.nl.
⁵ TNO-CBRN Protection, 2288GJ Rijswijk, The Netherlands. jan.langenberg@tno.nl.
⁶ TNO-CBRN Protection, 2288GJ Rijswijk, The Netherlands. daan.noort@tno.nl.
⁷ Ipsen Biopharmaceuticals, Basking Ridge, NJ 07920, USA. dsnyder@revance.com.
⁸ Ipsen Bioinnovation, Abingdon OX14 4RY, UK. keith.foster@ipsen.com.

The authors wish to make the following corrections to their paper [...].